PT-141 regulatory status: FDA approval and compounding access

The regulatory picture for PT-141 is actually clearer than for most peptides discussed in telehealth — because the active ingredient has FDA approval. The question is what that means for access.

Is PT-141 FDA approved

The active ingredient in PT-141 is bremelanotide, a synthetic peptide that acts on MC4R (melanocortin 4 receptor — in plain English: a brain receptor involved in sexual arousal and response). In 2019, the FDA approved bremelanotide under the brand name Vyleesi, developed by Palatin Technologies.

The approval is specifically for HSDD (hypoactive sexual desire disorder — persistent low sexual desire that causes personal distress) in premenopausal women. Vyleesi is administered via a prefilled auto-injector subcutaneously about 45 minutes before anticipated sexual activity.

This is the FDA-approved version: commercially manufactured, fixed dose, specific indication.

Compounded bremelanotide — commonly called PT-141 — is a different regulatory category. No compounded medication is FDA-approved by definition. It is legally prepared and dispensed by state-licensed 503A compounding pharmacies under a valid physician prescription. The 503A compounding framework has operated under the Food, Drug, and Cosmetic Act for decades and covers a wide range of therapeutic areas.

What is the difference between Vyleesi and compounded PT-141

The active pharmaceutical ingredient is bremelanotide in both cases. The differences are in format and regulatory status. Vyleesi is commercially manufactured in a specific auto-injector at a defined dose. Compounded PT-141 may be formulated at different concentrations, in different delivery formats, at the prescribing clinician's discretion.

This is meaningful because some clinicians prefer dosing flexibility that commercial formats do not accommodate. The 2026 peptide regulatory landscape provides broader context on how Category 1 and Category 2 compounds differ in their access structures.

Is compounded PT-141 legal

Yes, when prepared by a state-licensed 503A compounding pharmacy under a valid physician prescription. The legal framework is the same as for other compounded medications — state licensure sets the floor, federal FDCA provisions govern the compounding framework, and the prescribing physician's evaluation is the required entry point.

Anyone claiming a compounded peptide is "FDA-approved" or "FDA-cleared" is wrong — those phrases do not apply to compounded medications. The FDA's warning letter patterns in telehealth track exactly this kind of claim as a primary enforcement trigger.

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.